FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results